Prescription drug · ANDA
dexamethasone NDC 0904-7266
Dexamethasone 4 mg/1 · Tablet · Oral · Major Pharmaceuticals
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0904-7266-61 | 00904726661 | 100 BLISTER PACK in 1 CARTON (0904-7266-61) / 1 TABLET in 1 BLISTER PACKMarketed from Dec 2, 2022 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- dexamethasone
- Generic name (nonproprietary)
- dexamethasone
- Active ingredients
- Dexamethasone — 4 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Major Pharmaceuticals
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 215106
- Marketing start
- Listing expires
- Other FDA classes
- Corticosteroid Hormone Receptor Agonists (Mechanism)
- Identifiers
- Product ID 0904-7266_1c4b00a6-64d3-47f1-a206-b84aa969fd37SPL ID 1c4b00a6-64d3-47f1-a206-b84aa969fd37SPL set ID 64b46398-9b97-45e8-b1ba-1a202d574448RxCUI 197582, 197583UNII 7S5I7G3JQL
- Pharmacologic class
- Corticosteroid
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400904726661followed by a unit qualifier and the quantityPackage 00904-7266-61. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocortico…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 215106
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| dexamethasone | Dexamethasone 4 mg/1 | TabletOral | Cardinal Health 107, LLC | 55154-4315 |
| dexamethasone | Dexamethasone 6 mg/1 | TabletOral | Major Pharmaceuticals | 0904-7267 |
| dexamethasone | Dexamethasone 6 mg/1 | TabletOral | Preferred Pharmaceuticals Inc. | 68788-8293 |
| dexamethasone | Dexamethasone 4 mg/1 | TabletOral | Amneal Pharmaceuticals NY LLC | 60219-2043 |
| dexamethasone | Dexamethasone 6 mg/1 | TabletOral | Amneal Pharmaceuticals NY LLC | 60219-2044 |